Description of Invention:
This invention portrays a simple method for treatment of antigen-deficiency diseases by orally administering to a subject a therapeutically effective amount of the deficient antigen, wherein the antigen is not present in a liposome. This method increases hemostasis in a subject having hemophilia A or B, by orally administering to the hemophiliac a therapeutically effective amount of the appropriate clotting factor, sufficient to induce oral tolerance and supply exogenous clotting factor to the subject.
Inventors:
Oral Alpan et al. (NIAID)
Patent Status:
DHHS Reference No. E-281-2001/0 --
U.S. Provisional Application No. 60/310,150 filed 03 Aug 2001
PCT Application No. PCT/US02/24544 filed 02 Aug 2002, which published as WO 03/013244 on 20 Feb 2003
U.S. Patent Application No. 10/485,696 filed 02 Feb 2004
Portfolios: Internal Medicine
Internal Medicine-Therapeutics
For Additional Information Please Contact: Fatima Sayyid M.H.P.M.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301) 435-4521
Email: sayyidf@mail.nih.gov
Fax: (301) 402-0220
